revive: targeted therapy for uncontrolled erythrocytosis in pv with rusfertide
Published 1 year ago • 309 plays • Length 9:07Download video MP4
Download video MP3
Similar videos
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
5:42
an update on revive: rusfertide in patients with polycythemia vera
-
1:56
rationale for verify: rusfertide added to ongoing therapy in patients with polycythemia vera
-
2:15
vipor: a multi-targeted therapy for the treatment of r/r dlbcl
-
10:20
new guidelines for the treatment and management of polycythemia vera
-
2:25
master final analysis: quadruplet induction therapy, asct & mrd-adapted treatment cessation in ndmm
-
1:19
telomerase inhibition as a novel targeted therapy for myelofibrosis
-
1:12
contemporary challenges in polycythemia vera management
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
1:49
current and future therapies for pv: ropeginterferon alfa-2b
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:21
response-adapted therapy with copanlisib and rituximab for previously untreated fl
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
1:01
advancements in cml: improving treatment-free remission and novel agents
-
3:14
using machine learning to identify trajectories of hematotoxicity following car t-cell therapy
-
1:20
the impact of early ruxolitinib treatment on os in the comfort-i and comfort-ii studies
-
1:48
do all patients require maintenance therapy following allosct?
-
2:08
impact of bridging therapy on the outcomes of patients with r/r myeloma treated with ide-cel
-
1:56
treatment selection & sequencing in patients with relapsed, intolerant, or refractory myeloma